Agilent Beats Estimates and Raises 2025 Outlook on Lab-Market Strength

Agilent Technologies reported stronger-than-expected fiscal third-quarter results and lifted its full-year guidance, citing broad-based demand across laboratory markets despite continuing macroeconomic uncertainty and the recently imposed 145% U.S. tariff on Chinese goods. Revenue for the three months ended 31 July rose 10% from a year earlier to a record $1.74 billion, topping the $1.66 billion analysts anticipated. Non-GAAP earnings increased 4% to $1.37 a share, just ahead of the $1.36 consensus, while GAAP net income climbed 19% to $336 million, or $1.18 per share. All three business units grew, led by a 14% jump in the Life Sciences and Diagnostics group to $670 million. The quarter marked Agilent’s fifth straight period of sequential core-revenue acceleration, according to Chief Executive Padraig McDonnell. The Santa Clara-based company now expects fiscal-2025 revenue of $6.91 billion to $6.93 billion, up from a prior view of up to $6.88 billion, and projects non-GAAP earnings of $5.56 to $5.59 a share, compared with a previous range that topped out at $5.55. For the current quarter, Agilent forecasts revenue of $1.82 billion to $1.84 billion and earnings of $1.57 to $1.60 a share.